Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
Open Access
- 16 May 2019
- journal article
- review article
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3) , e00068
Abstract
The rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) poses a huge healthcare burden across the world. Although there are several antihyperglycaemic agents (AHAs) available including addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM do not achieve glycaemic targets, suggesting an urgent need for treatment strategies focusing on prevention and progression of T2DM and its long‐term complications. Lifestyle changes including implementation of healthy diet and physical activity are cornerstones for the management of T2DM. The positive effects of diet and exercise on incretin hormones such as glucagon‐like peptide‐1 (GLP‐1) have been reported. We hypothesize an IDEP concept (Interaction between Diet/Exercise and Pharmacotherapy) aimed at modifying the diet and lifestyle, along with pharmacotherapy to enhance the GLP‐1 levels, would result in good glycaemic control in patients with T2DM. Consuming protein‐rich food, avoiding saturated fatty acids and making small changes in eating habits such as eating slowly with longer mastication time can have a positive impact on the GLP‐1 secretion and insulin levels. Further the type of physical activity (aerobic/resistance training), intensity of exercise, duration, time and frequency of exercise have shown to improve GLP‐1 levels. Apart from AHAs, a few antihypertensive drugs and lipid‐lowering drugs have also shown to increase endogenous GLP‐1 levels, however, due to quick degradation of GLP‐1 by dipeptidyl peptidase‐4 (DPP‐4) enzyme, treatment with DPP‐4 inhibitors would protect GLP‐1 from degradation and prolong its activity. Thus, IDEP concept can be a promising treatment strategy, which positively influences the GLP‐1 levels and provide additive benefits in terms of improving metabolic parameters in patients with T2DM and slowing the progression of T2DM and its associated complications.Keywords
Funding Information
- Novartis
This publication has 115 references indexed in Scilit:
- Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptorDiabetologia, 2013
- Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary reportCardiovascular Diabetology, 2013
- Effects of Pre-Meal Drinks with Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite MealPLOS ONE, 2012
- The regulation of K‐ and L‐cell activity by GLUT2 and the calcium‐sensing receptor CasR in rat small intestineThe Journal of Physiology, 2012
- Angiotensin Receptor Blockade Increases Pancreatic Insulin Secretion and Decreases Glucose Intolerance during Glucose Supplementation in a Model of Metabolic SyndromeEndocrinology, 2012
- Cardiovascular Biology of the Incretin SystemEndocrine Reviews, 2012
- Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2Diabetes, 2012
- T1R3 taste receptor is critical for sucrose but not Polycose tasteAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat DietNew England Journal of Medicine, 2008
- Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1Proceedings of the National Academy of Sciences, 2007